Remove FDA Approval Remove Genomics Remove Packaging Remove Sales
article thumbnail

Bristol Myers Squibb Reports Second Quarter 2020 Financial Results

The Pharma Data

NEW YORK–( BUSINESS WIRE )– Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2020, which reflect strong product sales, continued advancement of the pipeline and robust operating performance. chairman and chief executive officer, Bristol Myers Squibb. Oncology and Hematology. Regulatory.

article thumbnail

Merck KGaA raises full-year forecast; Perlmutter’s new gig tackles ‘undruggable targets’

The Pharma Data

FDA approves 100th monoclonal antibody product ( Nature Reviews Drug Discovery ). New variant-hardy AbCellera-Lilly mAb shows utility of viral genomics surveillance ( BioCentury ). AI, digital health feature in latest batch of FDA breakthrough device designations ( MedTech Dive ).